SIK3

Across TCGA pan-cancer cohorts, SIK3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SIK3 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SIK3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SIK3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where SIK3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	III,IV	0.551	0.823	.026	6	view →
HNSC	OS	Median	All	0.992	0.944	.039	5	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
LSCC	DFS	Tertile	All	0.874	1.000	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SIK3–LUAD (OS)

Open the LUAD breakdown →